Recently troubled First Wave BioPharma, Inc. is adding pipeline and clinical development capability in an all-stock merger with privately held ImmunogenX, a deal announced on 18 December that will bring in Phase III-ready latiglutenase, an enzyme-replacement therapy that the two companies hope can become the first approved drug for celiac disease.
First Wave To Merge With ImmunogenX With Focus On Celiac Disease
Troubled by recent clinical disappointments, First Wave will combine with ImmunogenX to focus on that company’s Phase III-ready enzyme replacement therapy for celiac disease. A deep-pocketed partner waits in the wings.
